COVID-19 Ongoing Studies

Subject to their eligibility and consent, we are aiming for every patient with COVID-19 disease who is admitted to our hospitals to be given the opportunity to be part of one of the research trials or studies that we are running at Imperial. 

Summary of recruitment to our key studies:


Study Recruitment to date



C-19-ACS 119
Novel Coronavirus Observational Study (ISARIC) Tier 0: 1685
Tier 2: 87
Imperial Health Knowledge Bank 735
BioAID 1106
REACT-2 275
GenoMMIC 223
COVAC1 (Imperial Vaccine Study) 155
What’s the STORY? (Serum Testing Of Representative Youngsters) 100

Find out more about ongoing studies, including recruitment over time, by following links below.


RECAP: Remote COVID-19 Assessment in Primary Care

RECOVERY: Randomised Evaluation of COVID-19 Therapy

REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

C19-ACS: Preventing Cardiac Complications of COVID-19 Disease with Early Acute Coronary Syndrome Therapy

Gilead: Safety & Antiviral Activity of Remdesivir for COVID-19

COVACTA: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

COV001: A Study of a Candidate COVID-19 Vaccine


ISARIC: Coronavirus Clinical Characterisation Consortium

Imperial Health Knowledge Bank

BioAID: Bioresource for Adult Infectious Disease

OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic

DIAMONDS: Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis

PanSurge PREDICT: a global effort to collect data on all surgical patients presenting to hospital during the COVID19 pandemic

PAN-COVID: Pregnancy and Neonatal Outcomes in COVID-19

C19-RISP: The effect of Covid19 on Renal and Immuno-Suppressed Patients

What’s the STORY? Serum Testing Of Representative Youngsters